Shanghai Juncell Therapeutics Co., Ltd.

上海君赛生物股份有限公司

Develops cell therapies, notably tumor-infiltrating lymphocyte (TIL) therapies, for solid tumors. Its core candidate GC101 is the world's first TIL therapy not requiring high-intensity lymphodepletion chemotherapy or IL-2, per Frost & Sullivan, and operates in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Capacity and utilisation
• Cash burn and runway
• Adverse change after the track record
• Chapter 18A biotech